<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980655</url>
  </required_header>
  <id_info>
    <org_study_id>6115A1-3003</org_study_id>
    <secondary_id>B1851022</secondary_id>
    <nct_id>NCT00980655</nct_id>
  </id_info>
  <brief_title>Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients</brief_title>
  <official_title>A Phase 3, Open-label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13vPnC Followed by 23vPS in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years and Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more
      likely than other people to get ill from a germ called Streptococcus pneumoniae. Most people
      who have had a stem cell transplant are offered a vaccine called 23-valent pneumococcal
      polysaccharide vaccine (23vPS) to help protect against this germ. The purpose of this study
      is to evaluate the immune response in HSCT recipients who receive a 13 valent pneumococcal
      vaccine (13vPnC) followed by 23vPS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants</measure>
    <time_frame>Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 3</time_frame>
    <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 3 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 4</time_frame>
    <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 4 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants</measure>
    <time_frame>Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</measure>
    <time_frame>Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 4</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 4 blood draws.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 3, 1 month after 13vPnC Dose 4</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both after 13vPnC Dose 3 and after 13vPnC Dose 4 blood draws.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 1</measure>
    <time_frame>Within 14 days after 13vPnC Dose 1</time_frame>
    <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 2</measure>
    <time_frame>Within 14 days after 13vPnC Dose 2</time_frame>
    <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 3</measure>
    <time_frame>Within 14 days after 13vPnC Dose 3</time_frame>
    <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 4</measure>
    <time_frame>Within 14 days after 13vPnC Dose 4</time_frame>
    <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 1</measure>
    <time_frame>Within 14 days after 13vPnC Dose 1</time_frame>
    <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 2</measure>
    <time_frame>Within 14 days after 13vPnC Dose 2</time_frame>
    <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 3</measure>
    <time_frame>Within 14 days after 13vPnC Dose 3</time_frame>
    <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 4</measure>
    <time_frame>Within 14 days after 13vPnC Dose 4</time_frame>
    <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Vaccines, Pneumococcal Conjugate Vaccine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13vPnC</intervention_name>
    <description>0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.
Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23vPS</intervention_name>
    <description>0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject &gt;=2 years of age.

          -  Allogeneic HSCT for hematologic disorder.

          -  Allogeneic HSCT with full myeloablative conditioning or reduced intensity
             conditioning.

          -  Allogeneic HSCT approximately 3 to 6 months (91 days to 203 days) before enrollment.

          -  Stable engraftment (absolute neutrophil count (ANC) &gt;1000/µL; platelet count
             &gt;50,000/µL).

          -  Complete hematologic remission of underlying disease with very good partial remission
             (VGPR) acceptable in the case of lymphoma and myeloma.

          -  Subject or parent/legal guardian expected to be available for the entire study and can
             be contacted by telephone.

          -  Subject or parent/legal guardian must be able to complete an electronic diary
             (e-diary) and complete all relevant study procedures during study participation.

          -  Hematological recovery as defined by ANC &gt;1000/µL; platelet count &gt;50,000/µL.

          -  All female and male subjects who are biologically capable of having children must
             agree to abstinence or commit to the use of a reliable method of birth control from
             signing of the ICF until for 3 months after the last vaccination.

          -  Negative urine pregnancy test for all female subjects of child bearing potential.

        Exclusion Criteria:

          -  Autologous HSCT.

          -  Receipt of donor lymphocyte infusions during the 28 days preceding enrollment.

          -  Uncontrolled GVHD that in the opinion of the investigator would prevent the subject
             from participating in the study.

          -  Lansky/Karnofsky Score &lt;=60%.

          -  Receipt of plasma products or immunoglobulins during the 60 days preceding enrollment.

          -  Receipt of rituximab since HSCT.

          -  Receipt of chemotherapy for relapse of underlying malignant disease since HSCT.

          -  Human immunodeficiency virus (HIV) infection.

          -  Lymphoproliferative disorder since HSCT.

          -  Chronic illnesses with cardiac, pulmonary, renal, or liver failure that in the opinion
             of the investigator would prevent the subject participating in the study.

          -  Vaccination with any licensed or experimental pneumococcal vaccine since HSCT.

          -  Previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would in
             the opinion of the investigator contraindicate intramuscular injection.

          -  Participation in another study with ongoing use of an unlicensed investigational
             product from 28 days before study enrollment until the end of the study.

          -  Participation in another study with ongoing use of a licensed investigational product
             that in the opinion of the investigator would interfere with the evaluation of the
             study objectives.

          -  Permanent residence in a nursing home or other residential care facility.

          -  Pregnant or breastfeeding female subject.

          -  Subject who is a direct relative (child, grandchild, parent, or grandparent) of study
             personnel, or is a member of the study personnel.

          -  Receipt of advanced therapy medicinal products (ATMP) including gene therapy products,
             somatic cell therapy products, and tissue engineered products at any time before
             enrollment.

          -  If information is available, - previous allergic or anaphylactic reaction to any
             vaccine or vaccine-related component in a stem cell donor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bmo</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-223</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-345</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3003&amp;StudyName=Study%20to%20Evaluate%2013%20valent%20pneumococcal%20conjugate%20vaccine%20%2813vPnC%29%20Vaccine%20Followed%20by%2023-valent%20pneumococcal%20polysaccharide%20vaccine%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <results_first_submitted>March 17, 2014</results_first_submitted>
  <results_first_submitted_qc>March 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC, 23vPS (Pediatric Participants)</title>
          <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
        </group>
        <group group_id="P2">
          <title>13vPnC, 23vPS (Adult Participants)</title>
          <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 13vPnC Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 13vPnC Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 13vPnC Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 13vPnC Dose 4</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 23vPS Dose</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of investigational product and had safety data available.</population>
      <group_list>
        <group group_id="B1">
          <title>13vPnC, 23vPS (Pediatric Participants)</title>
          <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
        </group>
        <group group_id="B2">
          <title>13vPnC, 23vPS (Adult Participants)</title>
          <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="247"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.3" spread="4.41"/>
                    <measurement group_id="B2" value="47.3" spread="12.39"/>
                    <measurement group_id="B3" value="38.4" spread="19.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.</description>
        <time_frame>Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3</time_frame>
        <population>Evaluable immunogenicity population:eligible participants who received vaccination as assigned;had blood drawn within pre-specified time-frames;had at least 1 valid, determinate assay result; had no major protocol violation. N (number of participants analyzed)=participants evaluable for this measure, n=participants evaluable for specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.</description>
          <population>Evaluable immunogenicity population:eligible participants who received vaccination as assigned;had blood drawn within pre-specified time-frames;had at least 1 valid, determinate assay result; had no major protocol violation. N (number of participants analyzed)=participants evaluable for this measure, n=participants evaluable for specified serotype.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.96" lower_limit="13.63" upper_limit="23.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" lower_limit="3.98" upper_limit="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.85" lower_limit="17.61" upper_limit="32.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="2.46" upper_limit="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" lower_limit="4.18" upper_limit="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" lower_limit="3.99" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.28" lower_limit="8.15" upper_limit="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.76" lower_limit="4.63" upper_limit="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" lower_limit="3.72" upper_limit="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.22" lower_limit="6.36" upper_limit="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" lower_limit="3.10" upper_limit="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" lower_limit="5.15" upper_limit="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" lower_limit="6.11" upper_limit="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants</title>
        <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 3 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
        <time_frame>1 month after 13vPnC Dose 3</time_frame>
        <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants</title>
          <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 3 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
          <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=49, 147, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" lower_limit="2.38" upper_limit="5.19"/>
                    <measurement group_id="O2" value="2.05" lower_limit="1.53" upper_limit="2.76"/>
                    <measurement group_id="O3" value="2.35" lower_limit="1.84" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=49, 147, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.13" upper_limit="2.26"/>
                    <measurement group_id="O2" value="0.62" lower_limit="0.49" upper_limit="0.79"/>
                    <measurement group_id="O3" value="0.79" lower_limit="0.64" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=49, 147, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" lower_limit="2.68" upper_limit="6.36"/>
                    <measurement group_id="O2" value="1.78" lower_limit="1.35" upper_limit="2.34"/>
                    <measurement group_id="O3" value="2.20" lower_limit="1.73" upper_limit="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=48, 149, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" lower_limit="2.95" upper_limit="5.91"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.60" upper_limit="2.51"/>
                    <measurement group_id="O3" value="2.39" lower_limit="1.97" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=49, 148, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" lower_limit="5.16" upper_limit="11.23"/>
                    <measurement group_id="O2" value="3.31" lower_limit="2.53" upper_limit="4.33"/>
                    <measurement group_id="O3" value="4.07" lower_limit="3.25" upper_limit="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=48, 147, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" lower_limit="3.88" upper_limit="10.19"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.25" upper_limit="3.98"/>
                    <measurement group_id="O3" value="3.60" lower_limit="2.81" upper_limit="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=48, 149, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34" lower_limit="5.12" upper_limit="10.53"/>
                    <measurement group_id="O2" value="3.92" lower_limit="3.08" upper_limit="5.00"/>
                    <measurement group_id="O3" value="4.57" lower_limit="3.72" upper_limit="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=49, 149, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="3.01" upper_limit="5.78"/>
                    <measurement group_id="O2" value="2.44" lower_limit="1.93" upper_limit="3.10"/>
                    <measurement group_id="O3" value="2.79" lower_limit="2.29" upper_limit="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=49, 149, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" lower_limit="4.03" upper_limit="9.61"/>
                    <measurement group_id="O2" value="5.99" lower_limit="4.35" upper_limit="8.26"/>
                    <measurement group_id="O3" value="6.05" lower_limit="4.65" upper_limit="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=49, 148, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="2.90" upper_limit="5.98"/>
                    <measurement group_id="O2" value="3.04" lower_limit="2.37" upper_limit="3.91"/>
                    <measurement group_id="O3" value="3.29" lower_limit="2.67" upper_limit="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=49, 148, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.26" lower_limit="5.86" upper_limit="11.65"/>
                    <measurement group_id="O2" value="4.77" lower_limit="3.77" upper_limit="6.04"/>
                    <measurement group_id="O3" value="5.47" lower_limit="4.49" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=49, 148, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.80" lower_limit="3.80" upper_limit="8.84"/>
                    <measurement group_id="O2" value="3.48" lower_limit="2.69" upper_limit="4.50"/>
                    <measurement group_id="O3" value="3.95" lower_limit="3.17" upper_limit="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=49, 149, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" lower_limit="4.12" upper_limit="11.05"/>
                    <measurement group_id="O2" value="3.87" lower_limit="2.85" upper_limit="5.26"/>
                    <measurement group_id="O3" value="4.44" lower_limit="3.42" upper_limit="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</title>
        <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 4 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
        <time_frame>1 month after 13vPnC Dose 4</time_frame>
        <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</title>
          <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 4 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
          <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=38, 123, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.75" lower_limit="5.64" upper_limit="13.59"/>
                    <measurement group_id="O2" value="4.67" lower_limit="3.37" upper_limit="6.47"/>
                    <measurement group_id="O3" value="5.41" lower_limit="4.13" upper_limit="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=38, 123, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.89" upper_limit="1.70"/>
                    <measurement group_id="O2" value="0.91" lower_limit="0.71" upper_limit="1.17"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.79" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=36, 124, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.41" lower_limit="5.15" upper_limit="13.72"/>
                    <measurement group_id="O2" value="4.56" lower_limit="3.31" upper_limit="6.27"/>
                    <measurement group_id="O3" value="5.23" lower_limit="3.99" upper_limit="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=38, 122, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" lower_limit="6.07" upper_limit="11.70"/>
                    <measurement group_id="O2" value="5.57" lower_limit="4.28" upper_limit="7.26"/>
                    <measurement group_id="O3" value="6.15" lower_limit="4.95" upper_limit="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=37, 122, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.33" lower_limit="10.59" upper_limit="25.16"/>
                    <measurement group_id="O2" value="12.23" lower_limit="8.81" upper_limit="16.98"/>
                    <measurement group_id="O3" value="13.08" lower_limit="9.99" upper_limit="17.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=38, 124, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.13" lower_limit="11.15" upper_limit="29.47"/>
                    <measurement group_id="O2" value="12.13" lower_limit="8.63" upper_limit="17.06"/>
                    <measurement group_id="O3" value="13.33" lower_limit="10.04" upper_limit="17.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=38, 124, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.37" lower_limit="7.36" upper_limit="14.61"/>
                    <measurement group_id="O2" value="8.26" lower_limit="6.33" upper_limit="10.78"/>
                    <measurement group_id="O3" value="8.71" lower_limit="7.00" upper_limit="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=37, 124, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" lower_limit="5.21" upper_limit="11.61"/>
                    <measurement group_id="O2" value="5.09" lower_limit="3.93" upper_limit="6.59"/>
                    <measurement group_id="O3" value="5.61" lower_limit="4.50" upper_limit="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=37, 124, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.04" lower_limit="10.04" upper_limit="25.63"/>
                    <measurement group_id="O2" value="12.24" lower_limit="9.09" upper_limit="16.47"/>
                    <measurement group_id="O3" value="13.02" lower_limit="10.13" upper_limit="16.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=38, 122, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" lower_limit="4.04" upper_limit="10.59"/>
                    <measurement group_id="O2" value="6.69" lower_limit="5.01" upper_limit="8.93"/>
                    <measurement group_id="O3" value="6.65" lower_limit="5.20" upper_limit="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=37, 124, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.94" lower_limit="11.05" upper_limit="25.98"/>
                    <measurement group_id="O2" value="12.99" lower_limit="9.78" upper_limit="17.26"/>
                    <measurement group_id="O3" value="13.81" lower_limit="10.88" upper_limit="17.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=38, 123, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.96" lower_limit="12.19" upper_limit="32.68"/>
                    <measurement group_id="O2" value="13.69" lower_limit="9.93" upper_limit="18.88"/>
                    <measurement group_id="O3" value="14.96" lower_limit="11.42" upper_limit="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=38, 123, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.65" lower_limit="10.73" upper_limit="25.82"/>
                    <measurement group_id="O2" value="12.68" lower_limit="8.82" upper_limit="18.22"/>
                    <measurement group_id="O3" value="13.52" lower_limit="10.07" upper_limit="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.</description>
        <time_frame>Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3</time_frame>
        <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.</description>
          <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=48, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.64" lower_limit="16.75" upper_limit="45.62"/>
                    <measurement group_id="O2" value="15.54" lower_limit="11.20" upper_limit="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=48, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" lower_limit="4.74" upper_limit="12.13"/>
                    <measurement group_id="O2" value="4.43" lower_limit="3.35" upper_limit="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=49, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.83" lower_limit="23.84" upper_limit="69.95"/>
                    <measurement group_id="O2" value="19.86" lower_limit="13.83" upper_limit="28.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=47, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" lower_limit="2.86" upper_limit="5.90"/>
                    <measurement group_id="O2" value="2.70" lower_limit="2.15" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=48, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.49" lower_limit="4.79" upper_limit="11.72"/>
                    <measurement group_id="O2" value="4.79" lower_limit="3.57" upper_limit="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=47, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" lower_limit="3.79" upper_limit="9.55"/>
                    <measurement group_id="O2" value="4.94" lower_limit="3.60" upper_limit="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=48, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.65" lower_limit="9.63" upper_limit="22.28"/>
                    <measurement group_id="O2" value="9.15" lower_limit="6.95" upper_limit="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=48, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.64" lower_limit="5.40" upper_limit="10.82"/>
                    <measurement group_id="O2" value="5.26" lower_limit="4.02" upper_limit="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=49, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" lower_limit="2.83" upper_limit="8.86"/>
                    <measurement group_id="O2" value="4.92" lower_limit="3.53" upper_limit="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=49, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.59" lower_limit="7.84" upper_limit="20.21"/>
                    <measurement group_id="O2" value="7.13" lower_limit="5.27" upper_limit="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=49, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" lower_limit="3.38" upper_limit="7.51"/>
                    <measurement group_id="O2" value="3.58" lower_limit="2.72" upper_limit="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=49, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" lower_limit="4.67" upper_limit="12.57"/>
                    <measurement group_id="O2" value="6.44" lower_limit="4.69" upper_limit="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=49, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.73" lower_limit="5.79" upper_limit="16.34"/>
                    <measurement group_id="O2" value="7.52" lower_limit="5.46" upper_limit="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 4 blood draws.</description>
        <time_frame>Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 4</time_frame>
        <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 4 blood draws.</description>
          <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=37, 120, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.66" lower_limit="39.20" upper_limit="127.36"/>
                    <measurement group_id="O2" value="35.81" lower_limit="25.06" upper_limit="51.18"/>
                    <measurement group_id="O3" value="42.03" lower_limit="30.94" upper_limit="57.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=37, 120, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" lower_limit="3.25" upper_limit="10.61"/>
                    <measurement group_id="O2" value="6.41" lower_limit="4.74" upper_limit="8.66"/>
                    <measurement group_id="O3" value="6.28" lower_limit="4.81" upper_limit="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=36, 121, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.31" lower_limit="48.05" upper_limit="169.77"/>
                    <measurement group_id="O2" value="47.47" lower_limit="32.09" upper_limit="70.22"/>
                    <measurement group_id="O3" value="55.02" lower_limit="39.39" upper_limit="76.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=37, 119, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.76" lower_limit="4.81" upper_limit="12.51"/>
                    <measurement group_id="O2" value="7.29" lower_limit="5.32" upper_limit="9.99"/>
                    <measurement group_id="O3" value="7.40" lower_limit="5.69" upper_limit="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=36, 121, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.62" lower_limit="9.63" upper_limit="25.34"/>
                    <measurement group_id="O2" value="17.02" lower_limit="11.95" upper_limit="24.23"/>
                    <measurement group_id="O3" value="16.90" lower_limit="12.47" upper_limit="22.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=37, 122, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.90" lower_limit="9.76" upper_limit="29.25"/>
                    <measurement group_id="O2" value="20.09" lower_limit="13.94" upper_limit="28.94"/>
                    <measurement group_id="O3" value="19.29" lower_limit="14.22" upper_limit="26.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=38, 123, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.18" lower_limit="11.75" upper_limit="31.33"/>
                    <measurement group_id="O2" value="18.69" lower_limit="13.70" upper_limit="25.50"/>
                    <measurement group_id="O3" value="18.81" lower_limit="14.48" upper_limit="24.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=36, 122, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.90" lower_limit="9.55" upper_limit="23.25"/>
                    <measurement group_id="O2" value="11.13" lower_limit="8.27" upper_limit="14.99"/>
                    <measurement group_id="O3" value="11.90" lower_limit="9.27" upper_limit="15.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=37, 123, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.61" lower_limit="6.47" upper_limit="24.56"/>
                    <measurement group_id="O2" value="9.69" lower_limit="6.80" upper_limit="13.80"/>
                    <measurement group_id="O3" value="10.30" lower_limit="7.55" upper_limit="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=38, 121, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.22" lower_limit="12.05" upper_limit="37.36"/>
                    <measurement group_id="O2" value="14.40" lower_limit="10.17" upper_limit="20.41"/>
                    <measurement group_id="O3" value="15.80" lower_limit="11.76" upper_limit="21.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=37, 123, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" lower_limit="7.22" upper_limit="18.20"/>
                    <measurement group_id="O2" value="9.52" lower_limit="6.90" upper_limit="13.12"/>
                    <measurement group_id="O3" value="9.94" lower_limit="7.61" upper_limit="12.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=38, 120, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.31" lower_limit="16.63" upper_limit="51.64"/>
                    <measurement group_id="O2" value="25.63" lower_limit="17.56" upper_limit="37.43"/>
                    <measurement group_id="O3" value="26.47" lower_limit="19.31" upper_limit="36.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=38, 122, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.37" lower_limit="14.69" upper_limit="43.83"/>
                    <measurement group_id="O2" value="23.02" lower_limit="15.63" upper_limit="33.92"/>
                    <measurement group_id="O3" value="23.56" lower_limit="17.11" upper_limit="32.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both after 13vPnC Dose 3 and after 13vPnC Dose 4 blood draws.</description>
        <time_frame>1 month after 13vPnC Dose 3, 1 month after 13vPnC Dose 4</time_frame>
        <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both after 13vPnC Dose 3 and after 13vPnC Dose 4 blood draws.</description>
          <population>Evaluable immunogenicity population. Here 'N' (number of participants analyzed) signifies all participants who were evaluable for this measure and 'n' signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=37, 119, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" lower_limit="1.99" upper_limit="3.95"/>
                    <measurement group_id="O2" value="2.16" lower_limit="1.65" upper_limit="2.82"/>
                    <measurement group_id="O3" value="2.30" lower_limit="1.85" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=37, 119, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.64" upper_limit="1.22"/>
                    <measurement group_id="O2" value="1.32" lower_limit="1.07" upper_limit="1.62"/>
                    <measurement group_id="O3" value="1.20" lower_limit="1.01" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=35, 121, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.51" upper_limit="3.19"/>
                    <measurement group_id="O2" value="2.32" lower_limit="1.88" upper_limit="2.86"/>
                    <measurement group_id="O3" value="2.29" lower_limit="1.91" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=37, 119, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.74" upper_limit="2.93"/>
                    <measurement group_id="O2" value="2.43" lower_limit="1.94" upper_limit="3.06"/>
                    <measurement group_id="O3" value="2.39" lower_limit="1.99" upper_limit="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=36, 119, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" lower_limit="1.87" upper_limit="2.99"/>
                    <measurement group_id="O2" value="3.06" lower_limit="2.35" upper_limit="3.98"/>
                    <measurement group_id="O3" value="2.88" lower_limit="2.34" upper_limit="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=37, 120, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="2.09" upper_limit="4.19"/>
                    <measurement group_id="O2" value="3.10" lower_limit="2.44" upper_limit="3.95"/>
                    <measurement group_id="O3" value="3.07" lower_limit="2.51" upper_limit="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=36, 121, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.08" upper_limit="2.11"/>
                    <measurement group_id="O2" value="1.83" lower_limit="1.47" upper_limit="2.29"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.46" upper_limit="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=36, 121, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="1.43" upper_limit="3.03"/>
                    <measurement group_id="O2" value="1.82" lower_limit="1.48" upper_limit="2.23"/>
                    <measurement group_id="O3" value="1.88" lower_limit="1.57" upper_limit="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=36, 121, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.65" upper_limit="3.80"/>
                    <measurement group_id="O2" value="1.68" lower_limit="1.32" upper_limit="2.13"/>
                    <measurement group_id="O3" value="1.84" lower_limit="1.50" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=37, 118, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="1.24" upper_limit="2.16"/>
                    <measurement group_id="O2" value="1.87" lower_limit="1.54" upper_limit="2.28"/>
                    <measurement group_id="O3" value="1.81" lower_limit="1.54" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=36, 121, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.60" upper_limit="3.17"/>
                    <measurement group_id="O2" value="2.33" lower_limit="1.91" upper_limit="2.85"/>
                    <measurement group_id="O3" value="2.31" lower_limit="1.95" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=37, 120, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="2.15" upper_limit="5.68"/>
                    <measurement group_id="O2" value="3.65" lower_limit="2.90" upper_limit="4.59"/>
                    <measurement group_id="O3" value="3.61" lower_limit="2.94" upper_limit="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=37, 120, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" lower_limit="1.72" upper_limit="3.61"/>
                    <measurement group_id="O2" value="2.59" lower_limit="2.04" upper_limit="3.30"/>
                    <measurement group_id="O3" value="2.57" lower_limit="2.10" upper_limit="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 1</title>
        <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
        <time_frame>Within 14 days after 13vPnC Dose 1</time_frame>
        <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 1</title>
          <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
          <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: any (n = 38, 130, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="9.6" upper_limit="37.3"/>
                    <measurement group_id="O2" value="11.5" lower_limit="6.6" upper_limit="18.3"/>
                    <measurement group_id="O3" value="13.7" lower_limit="8.9" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: mild (n = 38, 130, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="6.0" upper_limit="31.3"/>
                    <measurement group_id="O2" value="10.8" lower_limit="6.0" upper_limit="17.4"/>
                    <measurement group_id="O3" value="11.9" lower_limit="7.4" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: moderate (n = 37, 128, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="3.0" upper_limit="25.4"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.2" upper_limit="5.5"/>
                    <measurement group_id="O3" value="3.6" lower_limit="1.3" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: severe (n = 37, 128, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: any (n = 40, 130, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="12.7" upper_limit="41.2"/>
                    <measurement group_id="O2" value="11.5" lower_limit="6.6" upper_limit="18.3"/>
                    <measurement group_id="O3" value="14.7" lower_limit="9.7" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: mild (n = 39, 130, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="2.9" upper_limit="24.2"/>
                    <measurement group_id="O2" value="10.8" lower_limit="6.0" upper_limit="17.4"/>
                    <measurement group_id="O3" value="10.7" lower_limit="6.4" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: moderate (n = 39, 128, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="9.3" upper_limit="36.5"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                    <measurement group_id="O3" value="5.4" lower_limit="2.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: severe (n = 37, 128, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: any (n = 51, 171, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" lower_limit="64.7" upper_limit="88.7"/>
                    <measurement group_id="O2" value="73.1" lower_limit="65.8" upper_limit="79.6"/>
                    <measurement group_id="O3" value="74.3" lower_limit="68.1" upper_limit="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: mild (n = 48, 169, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" lower_limit="53.7" upper_limit="81.3"/>
                    <measurement group_id="O2" value="69.8" lower_limit="62.3" upper_limit="76.6"/>
                    <measurement group_id="O3" value="69.6" lower_limit="63.0" upper_limit="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: moderate (n = 42, 138, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="29.8" upper_limit="61.3"/>
                    <measurement group_id="O2" value="22.5" lower_limit="15.8" upper_limit="30.3"/>
                    <measurement group_id="O3" value="27.8" lower_limit="21.4" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: severe (n = 37, 129, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.5" upper_limit="6.6"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 2</title>
        <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
        <time_frame>Within 14 days after 13vPnC Dose 2</time_frame>
        <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 2</title>
          <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
          <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: any (n = 28, 109, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="24.5" upper_limit="62.8"/>
                    <measurement group_id="O2" value="16.5" lower_limit="10.1" upper_limit="24.8"/>
                    <measurement group_id="O3" value="21.9" lower_limit="15.3" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: mild (n = 26, 108, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" lower_limit="17.2" upper_limit="55.7"/>
                    <measurement group_id="O2" value="15.7" lower_limit="9.4" upper_limit="24.0"/>
                    <measurement group_id="O3" value="19.4" lower_limit="13.1" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: moderate (n = 26, 103, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="11.6" upper_limit="47.8"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.2" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: severe (n = 24, 103, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.2" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: any (n = 28, 105, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="18.6" upper_limit="55.9"/>
                    <measurement group_id="O2" value="14.3" lower_limit="8.2" upper_limit="22.5"/>
                    <measurement group_id="O3" value="18.8" lower_limit="12.5" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: mild (n = 26, 105, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="4.4" upper_limit="34.9"/>
                    <measurement group_id="O2" value="14.3" lower_limit="8.2" upper_limit="22.5"/>
                    <measurement group_id="O3" value="14.5" lower_limit="9.0" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: moderate (n = 26, 102, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="11.6" upper_limit="47.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.6"/>
                    <measurement group_id="O3" value="5.5" lower_limit="2.2" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: severe (n = 24, 102, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: any (n = 40, 154, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="61.5" upper_limit="89.2"/>
                    <measurement group_id="O2" value="74.7" lower_limit="67.0" upper_limit="81.3"/>
                    <measurement group_id="O3" value="75.3" lower_limit="68.6" upper_limit="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: mild (n = 36, 148, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="49.0" upper_limit="81.4"/>
                    <measurement group_id="O2" value="70.9" lower_limit="62.9" upper_limit="78.1"/>
                    <measurement group_id="O3" value="70.1" lower_limit="62.9" upper_limit="76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: moderate (n = 32, 116, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" lower_limit="34.7" upper_limit="70.9"/>
                    <measurement group_id="O2" value="27.6" lower_limit="19.7" upper_limit="36.7"/>
                    <measurement group_id="O3" value="33.1" lower_limit="25.6" upper_limit="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: severe (n = 27, 104, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="4.2" upper_limit="33.7"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="4.6" lower_limit="1.7" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 3</title>
        <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
        <time_frame>Within 14 days after 13vPnC Dose 3</time_frame>
        <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 3</title>
          <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
          <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: any (n = 25, 95, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="14.9" upper_limit="53.5"/>
                    <measurement group_id="O2" value="9.5" lower_limit="4.4" upper_limit="17.2"/>
                    <measurement group_id="O3" value="14.2" lower_limit="8.5" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: mild (n = 24, 94, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="7.1" upper_limit="42.2"/>
                    <measurement group_id="O2" value="8.5" lower_limit="3.7" upper_limit="16.1"/>
                    <measurement group_id="O3" value="11.0" lower_limit="6.0" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: moderate (n = 24, 93, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="7.1" upper_limit="42.2"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.8"/>
                    <measurement group_id="O3" value="5.1" lower_limit="1.9" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: severe (n = 23, 93, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0.1" upper_limit="21.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.8"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.2" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: any (n = 28, 93, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="18.6" upper_limit="55.9"/>
                    <measurement group_id="O2" value="8.6" lower_limit="3.8" upper_limit="16.2"/>
                    <measurement group_id="O3" value="14.9" lower_limit="9.1" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: mild (n = 27, 93, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="11.1" upper_limit="46.3"/>
                    <measurement group_id="O2" value="8.6" lower_limit="3.8" upper_limit="16.2"/>
                    <measurement group_id="O3" value="12.5" lower_limit="7.2" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: moderate (n = 25, 92, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="6.8" upper_limit="40.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="4.3" lower_limit="1.4" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: severe (n = 23, 92, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0.1" upper_limit="21.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: any (n = 37, 138, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3" lower_limit="53.0" upper_limit="84.1"/>
                    <measurement group_id="O2" value="73.2" lower_limit="65.0" upper_limit="80.4"/>
                    <measurement group_id="O3" value="72.6" lower_limit="65.3" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: mild (n = 31, 132, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" lower_limit="45.4" upper_limit="80.8"/>
                    <measurement group_id="O2" value="67.4" lower_limit="58.7" upper_limit="75.3"/>
                    <measurement group_id="O3" value="66.9" lower_limit="59.1" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: moderate (n = 34, 107, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="22.2" upper_limit="56.4"/>
                    <measurement group_id="O2" value="27.1" lower_limit="19.0" upper_limit="36.6"/>
                    <measurement group_id="O3" value="29.8" lower_limit="22.4" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: severe (n = 24, 93, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.7" upper_limit="9.1"/>
                    <measurement group_id="O3" value="4.3" lower_limit="1.4" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 4</title>
        <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
        <time_frame>Within 14 days after 13vPnC Dose 4</time_frame>
        <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 4</title>
          <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters [cm] for participants aged 2 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to &lt;12 years and 5.5 to 10.0 cm for participants aged &gt;= 12 years); Severe (greater than [&gt;] 7.0 cm for participants aged 2 to &lt;12 years and &gt;10.0 cm for participants aged &gt;= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
          <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: any (n = 21, 79, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O2" value="22.8" lower_limit="14.1" upper_limit="33.6"/>
                    <measurement group_id="O3" value="33.0" lower_limit="23.9" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: mild (n = 20, 77, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="27.2" upper_limit="72.8"/>
                    <measurement group_id="O2" value="15.6" lower_limit="8.3" upper_limit="25.6"/>
                    <measurement group_id="O3" value="22.7" lower_limit="14.8" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: moderate (n = 18, 72, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="26.0" upper_limit="74.0"/>
                    <measurement group_id="O2" value="9.7" lower_limit="4.0" upper_limit="19.0"/>
                    <measurement group_id="O3" value="17.8" lower_limit="10.5" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: severe (n = 16, 73, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="5.6" lower_limit="1.8" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: any (n = 27, 81, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="46.0" upper_limit="83.5"/>
                    <measurement group_id="O2" value="28.4" lower_limit="18.9" upper_limit="39.5"/>
                    <measurement group_id="O3" value="38.0" lower_limit="28.8" upper_limit="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: mild (n = 21, 79, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O2" value="21.5" lower_limit="13.1" upper_limit="32.2"/>
                    <measurement group_id="O3" value="25.0" lower_limit="16.9" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: moderate (n = 23, 72, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="30.6" upper_limit="73.2"/>
                    <measurement group_id="O2" value="6.9" lower_limit="2.3" upper_limit="15.5"/>
                    <measurement group_id="O3" value="17.9" lower_limit="10.8" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: severe (n = 15, 73, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.2" upper_limit="31.9"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="4.5" lower_limit="1.3" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: any (n = 30, 113, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="69.3" upper_limit="96.2"/>
                    <measurement group_id="O2" value="77.0" lower_limit="68.1" upper_limit="84.4"/>
                    <measurement group_id="O3" value="79.0" lower_limit="71.4" upper_limit="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: mild (n = 25, 105, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="54.9" upper_limit="90.6"/>
                    <measurement group_id="O2" value="71.4" lower_limit="61.8" upper_limit="79.8"/>
                    <measurement group_id="O3" value="72.3" lower_limit="63.8" upper_limit="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: moderate (n = 24, 85, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="40.6" upper_limit="81.2"/>
                    <measurement group_id="O2" value="31.8" lower_limit="22.1" upper_limit="42.8"/>
                    <measurement group_id="O3" value="38.5" lower_limit="29.4" upper_limit="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: severe (n = 16, 74, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O2" value="5.4" lower_limit="1.5" upper_limit="13.3"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.5" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 1</title>
        <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
        <time_frame>Within 14 days after 13vPnC Dose 1</time_frame>
        <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 1</title>
          <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
          <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38 degrees C (n = 39, 130, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="4.3" upper_limit="27.4"/>
                    <measurement group_id="O2" value="6.2" lower_limit="2.7" upper_limit="11.8"/>
                    <measurement group_id="O3" value="7.7" lower_limit="4.2" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38, &lt;38.5 degrees C (n = 37, 130, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                    <measurement group_id="O2" value="6.2" lower_limit="2.7" upper_limit="11.8"/>
                    <measurement group_id="O3" value="6.0" lower_limit="2.9" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5, &lt;39 degrees C (n = 37, 128, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39, =&lt;40 degrees C (n = 39, 128, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="1.6" upper_limit="20.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                    <measurement group_id="O3" value="1.8" lower_limit="0.4" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n = 37, 128, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n = 45, 159, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="37.9" upper_limit="68.3"/>
                    <measurement group_id="O2" value="59.7" lower_limit="51.7" upper_limit="67.4"/>
                    <measurement group_id="O3" value="58.3" lower_limit="51.2" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n = 41, 149, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" lower_limit="22.1" upper_limit="53.1"/>
                    <measurement group_id="O2" value="49.0" lower_limit="40.7" upper_limit="57.3"/>
                    <measurement group_id="O3" value="46.3" lower_limit="39.1" upper_limit="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n = 44, 148, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O2" value="35.8" lower_limit="28.1" upper_limit="44.1"/>
                    <measurement group_id="O3" value="35.9" lower_limit="29.2" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n = 37, 136, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="3.0" upper_limit="25.4"/>
                    <measurement group_id="O2" value="11.8" lower_limit="6.9" upper_limit="18.4"/>
                    <measurement group_id="O3" value="11.6" lower_limit="7.2" upper_limit="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n = 42, 147, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="29.8" upper_limit="61.3"/>
                    <measurement group_id="O2" value="44.2" lower_limit="36.0" upper_limit="52.6"/>
                    <measurement group_id="O3" value="44.4" lower_limit="37.2" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n = 41, 145, 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="24.2" upper_limit="55.5"/>
                    <measurement group_id="O2" value="37.9" lower_limit="30.0" upper_limit="46.4"/>
                    <measurement group_id="O3" value="38.2" lower_limit="31.2" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n = 40, 134, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="9.1" upper_limit="35.6"/>
                    <measurement group_id="O2" value="17.2" lower_limit="11.2" upper_limit="24.6"/>
                    <measurement group_id="O3" value="17.8" lower_limit="12.4" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n = 37, 130, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.1" upper_limit="14.2"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.5" upper_limit="6.6"/>
                    <measurement group_id="O3" value="2.4" lower_limit="0.7" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (n = 39, 134, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="9.3" upper_limit="36.5"/>
                    <measurement group_id="O2" value="20.9" lower_limit="14.4" upper_limit="28.8"/>
                    <measurement group_id="O3" value="20.8" lower_limit="15.0" upper_limit="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n = 38, 134, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="7.7" upper_limit="34.3"/>
                    <measurement group_id="O2" value="17.9" lower_limit="11.8" upper_limit="25.5"/>
                    <measurement group_id="O3" value="18.0" lower_limit="12.6" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n = 38, 128, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.3" upper_limit="8.9"/>
                    <measurement group_id="O3" value="3.6" lower_limit="1.3" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n = 37, 128, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (n = 44, 145, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="18.6" upper_limit="47.6"/>
                    <measurement group_id="O2" value="35.9" lower_limit="28.1" upper_limit="44.2"/>
                    <measurement group_id="O3" value="34.9" lower_limit="28.1" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n = 44, 142, 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="18.6" upper_limit="47.6"/>
                    <measurement group_id="O2" value="33.8" lower_limit="26.1" upper_limit="42.2"/>
                    <measurement group_id="O3" value="33.3" lower_limit="26.6" upper_limit="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n = 38, 133, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="0.6" upper_limit="17.7"/>
                    <measurement group_id="O2" value="9.0" lower_limit="4.7" upper_limit="15.2"/>
                    <measurement group_id="O3" value="8.2" lower_limit="4.5" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n = 37, 131, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.3" upper_limit="8.7"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Any (n = 47, 154, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="40.1" upper_limit="69.8"/>
                    <measurement group_id="O2" value="50.0" lower_limit="41.8" upper_limit="58.2"/>
                    <measurement group_id="O3" value="51.2" lower_limit="44.1" upper_limit="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Mild (n = 43, 148, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="31.2" upper_limit="62.3"/>
                    <measurement group_id="O2" value="42.6" lower_limit="34.5" upper_limit="51.0"/>
                    <measurement group_id="O3" value="43.5" lower_limit="36.3" upper_limit="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Moderate (n = 44, 139, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O2" value="21.6" lower_limit="15.1" upper_limit="29.4"/>
                    <measurement group_id="O3" value="25.1" lower_limit="19.0" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Severe (n = 37, 131, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                    <measurement group_id="O2" value="5.3" lower_limit="2.2" upper_limit="10.7"/>
                    <measurement group_id="O3" value="5.4" lower_limit="2.5" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Any (n = 38, 143, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="13.4" upper_limit="43.1"/>
                    <measurement group_id="O2" value="26.6" lower_limit="19.5" upper_limit="34.6"/>
                    <measurement group_id="O3" value="26.5" lower_limit="20.2" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Mild (n = 37, 139, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="8.0" upper_limit="35.2"/>
                    <measurement group_id="O2" value="19.4" lower_limit="13.2" upper_limit="27.0"/>
                    <measurement group_id="O3" value="19.3" lower_limit="13.8" upper_limit="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Moderate (n = 38, 137, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="6.0" upper_limit="31.3"/>
                    <measurement group_id="O2" value="14.6" lower_limit="9.2" upper_limit="21.6"/>
                    <measurement group_id="O3" value="14.9" lower_limit="9.9" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Severe (n = 37, 130, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.1" upper_limit="14.2"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.8" upper_limit="7.7"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Pain (n= 40, 136, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="12.7" upper_limit="41.2"/>
                    <measurement group_id="O2" value="13.2" lower_limit="8.0" upper_limit="20.1"/>
                    <measurement group_id="O3" value="15.9" lower_limit="10.8" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Fever (n= 41, 133, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="12.4" upper_limit="40.3"/>
                    <measurement group_id="O2" value="14.3" lower_limit="8.8" upper_limit="21.4"/>
                    <measurement group_id="O3" value="16.7" lower_limit="11.5" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 2</title>
        <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
        <time_frame>Within 14 days after 13vPnC Dose 2</time_frame>
        <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 2</title>
          <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
          <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38 degrees C (n = 26, 105, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="9.0" upper_limit="43.6"/>
                    <measurement group_id="O2" value="6.7" lower_limit="2.7" upper_limit="13.3"/>
                    <measurement group_id="O3" value="9.9" lower_limit="5.4" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38, &lt;38.5 degrees C (n = 26, 105, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="6.6" upper_limit="39.4"/>
                    <measurement group_id="O2" value="5.7" lower_limit="2.1" upper_limit="12.0"/>
                    <measurement group_id="O3" value="8.4" lower_limit="4.3" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5, &lt;39 degrees C (n = 24, 102, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O3" value="2.4" lower_limit="0.5" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39, =&lt;40 degrees C (n = 24, 102, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O3" value="2.4" lower_limit="0.5" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n = 24, 102, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n = 38, 133, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="43.4" upper_limit="76.0"/>
                    <measurement group_id="O2" value="56.4" lower_limit="47.5" upper_limit="65.0"/>
                    <measurement group_id="O3" value="57.3" lower_limit="49.5" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n = 31, 125, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="27.3" upper_limit="64.0"/>
                    <measurement group_id="O2" value="39.2" lower_limit="30.6" upper_limit="48.3"/>
                    <measurement group_id="O3" value="40.4" lower_limit="32.6" upper_limit="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n = 33, 122, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="28.1" upper_limit="63.6"/>
                    <measurement group_id="O2" value="37.7" lower_limit="29.1" upper_limit="46.9"/>
                    <measurement group_id="O3" value="39.4" lower_limit="31.6" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n = 24, 107, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="2.7" upper_limit="32.4"/>
                    <measurement group_id="O2" value="9.3" lower_limit="4.6" upper_limit="16.5"/>
                    <measurement group_id="O3" value="9.9" lower_limit="5.4" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n = 31, 121,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="16.7" upper_limit="51.4"/>
                    <measurement group_id="O2" value="35.5" lower_limit="27.0" upper_limit="44.8"/>
                    <measurement group_id="O3" value="34.9" lower_limit="27.3" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n = 30, 117, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="14.7" upper_limit="49.4"/>
                    <measurement group_id="O2" value="29.9" lower_limit="21.8" upper_limit="39.1"/>
                    <measurement group_id="O3" value="29.9" lower_limit="22.7" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n = 26, 110, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                    <measurement group_id="O2" value="16.4" lower_limit="10.0" upper_limit="24.6"/>
                    <measurement group_id="O3" value="14.7" lower_limit="9.2" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n = 24, 104, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (n = 28, 107, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="8.3" upper_limit="41.0"/>
                    <measurement group_id="O2" value="13.1" lower_limit="7.3" upper_limit="21.0"/>
                    <measurement group_id="O3" value="14.8" lower_limit="9.3" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n = 27, 107, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="6.3" upper_limit="38.1"/>
                    <measurement group_id="O2" value="10.3" lower_limit="5.2" upper_limit="17.7"/>
                    <measurement group_id="O3" value="11.9" lower_limit="7.0" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n = 28, 103, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="4.0" upper_limit="32.7"/>
                    <measurement group_id="O2" value="4.9" lower_limit="1.6" upper_limit="11.0"/>
                    <measurement group_id="O3" value="6.9" lower_limit="3.2" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n = 24, 102, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (n = 29, 121, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="15.3" upper_limit="50.8"/>
                    <measurement group_id="O2" value="28.9" lower_limit="21.0" upper_limit="37.9"/>
                    <measurement group_id="O3" value="29.3" lower_limit="22.2" upper_limit="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n = 29, 120, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="15.3" upper_limit="50.8"/>
                    <measurement group_id="O2" value="26.7" lower_limit="19.0" upper_limit="35.5"/>
                    <measurement group_id="O3" value="27.5" lower_limit="20.5" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n = 25, 109, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="10.1" lower_limit="5.1" upper_limit="17.3"/>
                    <measurement group_id="O3" value="9.7" lower_limit="5.3" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n = 24, 103, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.2" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Any (n = 36, 124, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="27.9" upper_limit="61.9"/>
                    <measurement group_id="O2" value="45.2" lower_limit="36.2" upper_limit="54.3"/>
                    <measurement group_id="O3" value="45.0" lower_limit="37.1" upper_limit="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Mild (n = 32, 118, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="16.1" upper_limit="50.0"/>
                    <measurement group_id="O2" value="37.3" lower_limit="28.6" upper_limit="46.7"/>
                    <measurement group_id="O3" value="36.0" lower_limit="28.3" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Moderate (n = 32, 111, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="21.1" upper_limit="56.3"/>
                    <measurement group_id="O2" value="25.2" lower_limit="17.5" upper_limit="34.4"/>
                    <measurement group_id="O3" value="28.0" lower_limit="20.8" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Severe (n = 25, 106, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="5.7" lower_limit="2.1" upper_limit="11.9"/>
                    <measurement group_id="O3" value="6.1" lower_limit="2.7" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Any (n = 31, 116, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="16.7" upper_limit="51.4"/>
                    <measurement group_id="O2" value="23.3" lower_limit="15.9" upper_limit="32.0"/>
                    <measurement group_id="O3" value="25.2" lower_limit="18.4" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Mild (n = 27, 115, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="6.3" upper_limit="38.1"/>
                    <measurement group_id="O2" value="21.7" lower_limit="14.6" upper_limit="30.4"/>
                    <measurement group_id="O3" value="21.1" lower_limit="14.7" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Moderate (n = 30, 106, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="14.7" upper_limit="49.4"/>
                    <measurement group_id="O2" value="10.4" lower_limit="5.3" upper_limit="17.8"/>
                    <measurement group_id="O3" value="14.7" lower_limit="9.2" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Severe (n = 25, 104, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.5" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Pain (n= 28, 105, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="10.7" upper_limit="44.9"/>
                    <measurement group_id="O2" value="7.6" lower_limit="3.3" upper_limit="14.5"/>
                    <measurement group_id="O3" value="11.3" lower_limit="6.5" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Fever (n= 27, 107, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="16.5" upper_limit="54.0"/>
                    <measurement group_id="O2" value="10.3" lower_limit="5.2" upper_limit="17.7"/>
                    <measurement group_id="O3" value="14.9" lower_limit="9.4" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 3</title>
        <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
        <time_frame>Within 14 days after 13vPnC Dose 3</time_frame>
        <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 3</title>
          <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
          <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38 degrees C (n = 27, 93, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="4.2" upper_limit="33.7"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.2" upper_limit="10.6"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.9" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38, &lt;38.5 degrees C (n = 26, 93, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="2.4" upper_limit="30.2"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.7" upper_limit="9.1"/>
                    <measurement group_id="O3" value="5.0" lower_limit="1.9" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5, &lt;39 degrees C (n = 24, 93, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.7" upper_limit="9.1"/>
                    <measurement group_id="O3" value="3.4" lower_limit="0.9" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39, =&lt;40 degrees C (n = 24, 92, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.2" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n = 23, 92, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n = 35, 122, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" lower_limit="31.4" upper_limit="66.0"/>
                    <measurement group_id="O2" value="49.2" lower_limit="40.0" upper_limit="58.4"/>
                    <measurement group_id="O3" value="49.0" lower_limit="41.0" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n = 32, 116, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="23.7" upper_limit="59.4"/>
                    <measurement group_id="O2" value="38.8" lower_limit="29.9" upper_limit="48.3"/>
                    <measurement group_id="O3" value="39.2" lower_limit="31.3" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n = 30, 107, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="17.3" upper_limit="52.8"/>
                    <measurement group_id="O2" value="29.9" lower_limit="21.4" upper_limit="39.5"/>
                    <measurement group_id="O3" value="30.7" lower_limit="23.1" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n = 24, 96, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="7.3" lower_limit="3.0" upper_limit="14.4"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.9" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n = 32, 110,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="21.1" upper_limit="56.3"/>
                    <measurement group_id="O2" value="37.3" lower_limit="28.2" upper_limit="47.0"/>
                    <measurement group_id="O3" value="37.3" lower_limit="29.4" upper_limit="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n = 30, 108, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="14.7" upper_limit="49.4"/>
                    <measurement group_id="O2" value="32.4" lower_limit="23.7" upper_limit="42.1"/>
                    <measurement group_id="O3" value="31.9" lower_limit="24.2" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n = 27, 95, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="8.6" upper_limit="42.3"/>
                    <measurement group_id="O2" value="15.8" lower_limit="9.1" upper_limit="24.7"/>
                    <measurement group_id="O3" value="17.2" lower_limit="11.0" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n = 25, 94, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="3.4" lower_limit="0.9" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (n = 25, 95, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="11.6" lower_limit="5.9" upper_limit="19.8"/>
                    <measurement group_id="O3" value="10.8" lower_limit="5.9" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n = 24, 95, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="5.3" lower_limit="1.7" upper_limit="11.9"/>
                    <measurement group_id="O3" value="5.0" lower_limit="1.9" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n = 24, 93, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="7.5" lower_limit="3.1" upper_limit="14.9"/>
                    <measurement group_id="O3" value="6.8" lower_limit="3.0" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n = 23, 92, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (n = 26, 104, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="4.4" upper_limit="34.9"/>
                    <measurement group_id="O2" value="25.0" lower_limit="17.0" upper_limit="34.4"/>
                    <measurement group_id="O3" value="23.1" lower_limit="16.1" upper_limit="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n = 26, 102, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="4.4" upper_limit="34.9"/>
                    <measurement group_id="O2" value="21.6" lower_limit="14.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="20.3" lower_limit="13.7" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n = 24, 95, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="5.3" lower_limit="1.7" upper_limit="11.9"/>
                    <measurement group_id="O3" value="5.0" lower_limit="1.9" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n = 23, 94, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.2" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Any (n = 35, 117, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" lower_limit="28.8" upper_limit="63.4"/>
                    <measurement group_id="O2" value="38.5" lower_limit="29.6" upper_limit="47.9"/>
                    <measurement group_id="O3" value="40.1" lower_limit="32.3" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Mild (n = 30, 112, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="17.3" upper_limit="52.8"/>
                    <measurement group_id="O2" value="33.0" lower_limit="24.4" upper_limit="42.6"/>
                    <measurement group_id="O3" value="33.1" lower_limit="25.4" upper_limit="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Moderate (n = 31, 101, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="16.7" upper_limit="51.4"/>
                    <measurement group_id="O2" value="16.8" lower_limit="10.1" upper_limit="25.6"/>
                    <measurement group_id="O3" value="20.5" lower_limit="13.9" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Severe (n = 24, 94, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.7" upper_limit="9.0"/>
                    <measurement group_id="O3" value="3.4" lower_limit="0.9" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Any (n = 28, 104, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="10.7" upper_limit="44.9"/>
                    <measurement group_id="O2" value="20.2" lower_limit="13.0" upper_limit="29.2"/>
                    <measurement group_id="O3" value="21.2" lower_limit="14.6" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Mild (n = 26, 102, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="6.6" upper_limit="39.4"/>
                    <measurement group_id="O2" value="17.6" lower_limit="10.8" upper_limit="26.4"/>
                    <measurement group_id="O3" value="18.0" lower_limit="11.7" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Moderate (n = 27, 95, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="6.3" upper_limit="38.1"/>
                    <measurement group_id="O2" value="8.4" lower_limit="3.7" upper_limit="15.9"/>
                    <measurement group_id="O3" value="10.7" lower_limit="5.8" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Severe (n = 25, 94, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="3.4" lower_limit="0.9" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Pain (n= 28, 97, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="8.3" upper_limit="41.0"/>
                    <measurement group_id="O2" value="12.4" lower_limit="6.6" upper_limit="20.6"/>
                    <measurement group_id="O3" value="14.4" lower_limit="8.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Fever (n= 30, 101, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="12.3" upper_limit="45.9"/>
                    <measurement group_id="O2" value="15.8" lower_limit="9.3" upper_limit="24.4"/>
                    <measurement group_id="O3" value="18.3" lower_limit="12.1" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 4</title>
        <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
        <time_frame>Within 14 days after 13vPnC Dose 4</time_frame>
        <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Pediatric participants aged 2 to 17 years received 4 single 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injections followed by single 0.5 mL dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Adult participants aged 18 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>All participants aged 2 years and above received 4 single 0.5 mL doses of 13vPnC intramuscular injections followed by single 0.5 mL dose of 23vPS intramuscular injection. 13vPnC Doses 1 to 3 were administered at 1-month intervals, 13vPnC Dose 4 was administered at 6 months after 13vPnC Dose 3, and 23vPS was administered 1 month after 13vPnC Dose 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 4</title>
          <description>Specific systemic events (fever &gt;=38 degrees Celsius [C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours).</description>
          <population>Safety population. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38 degrees C (n= 18, 78, 96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" lower_limit="9.7" upper_limit="53.5"/>
                    <measurement group_id="O2" value="15.4" lower_limit="8.2" upper_limit="25.3"/>
                    <measurement group_id="O3" value="17.7" lower_limit="10.7" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38, &lt;38.5 degrees C (n = 16, 76, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O2" value="13.2" lower_limit="6.5" upper_limit="22.9"/>
                    <measurement group_id="O3" value="13.0" lower_limit="6.9" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5, &lt;39 degrees C (n = 17, 73, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="3.8" upper_limit="43.4"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.3" upper_limit="9.5"/>
                    <measurement group_id="O3" value="5.6" lower_limit="1.8" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39, =&lt;40 degrees C (n = 15, 72, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="21.8"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.3" upper_limit="9.7"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.3" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n = 15, 71, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="21.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n = 28, 100, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" lower_limit="47.6" upper_limit="84.1"/>
                    <measurement group_id="O2" value="67.0" lower_limit="56.9" upper_limit="76.1"/>
                    <measurement group_id="O3" value="67.2" lower_limit="58.3" upper_limit="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n = 26, 95, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="40.6" upper_limit="79.8"/>
                    <measurement group_id="O2" value="54.7" lower_limit="44.2" upper_limit="65.0"/>
                    <measurement group_id="O3" value="56.2" lower_limit="46.9" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n = 20, 86, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" lower_limit="23.1" upper_limit="68.5"/>
                    <measurement group_id="O2" value="45.3" lower_limit="34.6" upper_limit="56.5"/>
                    <measurement group_id="O3" value="45.3" lower_limit="35.6" upper_limit="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n = 16, 77, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O2" value="13.0" lower_limit="6.4" upper_limit="22.6"/>
                    <measurement group_id="O3" value="12.9" lower_limit="6.8" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n = 21, 93, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O2" value="45.2" lower_limit="34.8" upper_limit="55.8"/>
                    <measurement group_id="O3" value="46.5" lower_limit="37.1" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n = 21, 88, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="25.7" upper_limit="70.2"/>
                    <measurement group_id="O2" value="38.6" lower_limit="28.4" upper_limit="49.6"/>
                    <measurement group_id="O3" value="40.4" lower_limit="31.1" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n = 16, 82, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="4.0" upper_limit="45.6"/>
                    <measurement group_id="O2" value="28.0" lower_limit="18.7" upper_limit="39.1"/>
                    <measurement group_id="O3" value="26.5" lower_limit="18.1" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n = 16, 74, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O2" value="5.4" lower_limit="1.5" upper_limit="13.3"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.5" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (n = 16, 73, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="0.2" upper_limit="30.2"/>
                    <measurement group_id="O2" value="5.5" lower_limit="1.5" upper_limit="13.4"/>
                    <measurement group_id="O3" value="5.6" lower_limit="1.8" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n = 16, 73, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="0.2" upper_limit="30.2"/>
                    <measurement group_id="O2" value="5.5" lower_limit="1.5" upper_limit="13.4"/>
                    <measurement group_id="O3" value="5.6" lower_limit="1.8" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n = 15, 71, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="21.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n = 15, 71, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="21.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (n = 18, 83, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="6.4" upper_limit="47.6"/>
                    <measurement group_id="O2" value="30.1" lower_limit="20.5" upper_limit="41.2"/>
                    <measurement group_id="O3" value="28.7" lower_limit="20.1" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n = 18, 82, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="6.4" upper_limit="47.6"/>
                    <measurement group_id="O2" value="29.3" lower_limit="19.7" upper_limit="40.4"/>
                    <measurement group_id="O3" value="28.0" lower_limit="19.5" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n = 15, 72, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="21.8"/>
                    <measurement group_id="O2" value="4.2" lower_limit="0.9" upper_limit="11.7"/>
                    <measurement group_id="O3" value="3.4" lower_limit="0.7" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n = 15, 72, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="21.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Any (n = 24, 99, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" lower_limit="36.6" upper_limit="77.9"/>
                    <measurement group_id="O2" value="60.6" lower_limit="50.3" upper_limit="70.3"/>
                    <measurement group_id="O3" value="60.2" lower_limit="50.9" upper_limit="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Mild (n = 22, 92, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="28.2" upper_limit="71.8"/>
                    <measurement group_id="O2" value="50.0" lower_limit="39.4" upper_limit="60.6"/>
                    <measurement group_id="O3" value="50.0" lower_limit="40.5" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Moderate (n = 19, 80, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" lower_limit="16.3" upper_limit="61.6"/>
                    <measurement group_id="O2" value="30.0" lower_limit="20.3" upper_limit="41.3"/>
                    <measurement group_id="O3" value="31.3" lower_limit="22.4" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Severe (n = 16, 75, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O2" value="6.7" lower_limit="2.2" upper_limit="14.9"/>
                    <measurement group_id="O3" value="7.7" lower_limit="3.1" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Any (n = 16, 83, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="7.3" upper_limit="52.4"/>
                    <measurement group_id="O2" value="32.5" lower_limit="22.6" upper_limit="43.7"/>
                    <measurement group_id="O3" value="31.3" lower_limit="22.4" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Mild (n = 15, 78, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="1.7" upper_limit="40.5"/>
                    <measurement group_id="O2" value="24.4" lower_limit="15.3" upper_limit="35.4"/>
                    <measurement group_id="O3" value="22.6" lower_limit="14.6" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Moderate (n = 16, 75, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O2" value="17.3" lower_limit="9.6" upper_limit="27.8"/>
                    <measurement group_id="O3" value="16.5" lower_limit="9.5" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Severe (n = 16, 74, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="0.2" upper_limit="30.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0.8" upper_limit="11.4"/>
                    <measurement group_id="O3" value="4.4" lower_limit="1.2" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Pain (n= 16, 77, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="4.0" upper_limit="45.6"/>
                    <measurement group_id="O2" value="16.9" lower_limit="9.3" upper_limit="27.1"/>
                    <measurement group_id="O3" value="17.2" lower_limit="10.2" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Fever (n= 17, 77, 94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="6.8" upper_limit="49.9"/>
                    <measurement group_id="O2" value="15.6" lower_limit="8.3" upper_limit="25.6"/>
                    <measurement group_id="O3" value="17.0" lower_limit="10.1" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs/SAEs: recorded from 13vPnC Dose 1 to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events (up to 14 days after 13vPnC vaccination)</time_frame>
      <desc>SAEs and AEs were grouped by system organ class and summarized. AEs included AEs collected in electronic diary (local,systemic reactions for 13vPnC; systematic assessment) and AEs collected on case report form at each visit (nonsystematic assessment). Participants who received specified dose and had safety data available were evaluable for safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Dose 1 to 13vPnC Dose 3 Blood Draw</title>
          <description>All participants aged 2 years and above who received 3 single 0.5 mL doses of 13vPnC intramuscular injections at 1-month intervals, were assessed from 13vPnC Dose 1 to the blood draw 1 month after 13vPnC Dose 3.</description>
        </group>
        <group group_id="E2">
          <title>13vPnC Dose 3 Blood Draw to 13vPnC Dose 4</title>
          <description>All participants aged 2 years and above who received 4 single 0.5 mL doses of 13vPnC intramuscular injections, 13vPnC Doses 1 to 3 at 1-month intervals and 13vPnC Dose 4 at 6 months after 13vPnC Dose 3, were assessed from blood draw 1 month after 13vPnC Dose 3 to prior to administration of 13vPnC Dose 4.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Dose 4</title>
          <description>All participants aged 2 years and above who received 4 single 0.5 mL doses of 13vPnC intramuscular injections, 13vPnC Doses 1 to 3 at 1-month intervals and 13vPnC Dose 4 at 6 months after 13vPnC Dose 3, were assessed from 13vPnC Dose 4 to the blood draw 1 month after 13vPnC Dose 4.</description>
        </group>
        <group group_id="E4">
          <title>23vPS Dose</title>
          <description>All participants aged 2 years and above who received 4 single 0.5 mL doses of 13vPnC intramuscular injections, 13vPnC Doses 1 to 3 at 1-month intervals and 13vPnC Dose 4 at 6 months after 13vPnC Dose 3, followed by single 0.5 mL dose of 23vPS intramuscular injection at 1 month after 13vPnC Dose 4, were assessed from 23vPS Dose to the blood draw 1 month after 23vPS Dose.</description>
        </group>
        <group group_id="E5">
          <title>Follow-up</title>
          <description>All participants aged 2 years and above who received 4 single 0.5 mL doses of 13vPnC intramuscular injections, 13vPnC Doses 1 to 3 at 1-month intervals and 13vPnC Dose 4 at 6 months after 13vPnC Dose 3, followed by single 0.5 mL dose of 23vPS intramuscular injection at 1 month after 13vPnC Dose 4, were assessed from blood draw 1 month after 23vPS Dose to 6-month follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Anaemia haemolytic autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Warm type haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title vocab="No coding system">Uncoded</sub_title>
                <description>Term was not coded because it violated sponsor’s coding conventions.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in intestine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Haemophilus sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hepatic candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonas aeruginosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis septic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>False positive investigation result</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ependymoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Refractory anaemia with an excess of blasts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Juvenile chronic myelomonocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dilatation ventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Myotonic dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ichthyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cushing's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oestrogen deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Allergic keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Orbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Aptyalism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral mucosal discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tongue coated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Catheter site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Complication of device removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site movement impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vaccination site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vaccination site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vaccination site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vaccination site oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vaccination site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38, &lt;38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38.5, &lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=39, =&lt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="128"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="121"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38, &lt;38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38.5, &lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=39, =&lt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38, &lt;38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=38.5, &lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=39, =&lt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Muscle pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Joint pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in liver</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypogammaglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Enterobacter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Mycoplasma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Streptococcal urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Injection site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Trichosporon infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Febrile nonhaemolytic transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Conjunctival scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Drug administration error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Human herpes virus 6 serology positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Thyroxine decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Serum ferritin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cystogram</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ejection fraction abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vitamin K deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Precursor B-lymphoblastic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cranial nerve palsies multiple</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Genital discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oropharyngeal plaque</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Generalised erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lichenification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Perivascular dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pityriasis rubra pilaris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 1 and Dose 4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 3</description>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC Dose 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vasodilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

